- Johnson Controls International PLC JCI has signed a joint development agreement with Phylagen, a biotechnology company in microbiome optimization of indoor environments.
- The agreement includes a strategic investment in Phylagen. The financial terms of the deal were not disclosed.
- Through this agreement, the companies develop cutting-edge technology that leverages the science of building microbiomes to improve the future of healthy buildings.
- Price Action: JCI shares traded higher by 1.87% at $74.18 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
